MC
Merck & Co Portfolio holdings
AUM
$216M
This Quarter Return
+45.19%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$216M
AUM Growth
+$216M
(+31%)
Cap. Flow
+$31.1K
Cap. Flow
% of AUM
0.01%
Top 10 Holdings %
Top 10 Hldgs %
99.68%
Holding
13
New
1
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
HURA
TuHURA Biosciences, Inc. Common Stock
HURA
|
$31.1K |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Personalis
PSNL
$434M
| $92.1M | 42.73% | 14,044,943 | – | – |
|
2
Moderna
MRNA
$9.37B
| $63.7M | 29.54% | 2,308,190 | – | – |
|
3
Kymera Therapeutics
KYMR
$2.95B
| $33.7M | 15.63% | 772,165 | – | – |
|
4
Entrada Therapeutics
TRDA
$208M
| $11.7M | 5.42% | 1,739,768 | – | – |
|
5
Alector
ALEC
$238M
| $4.96M | 2.3% | 3,545,719 | – | – |
|
|
EVAX
6
Evaxion A/S American Depositary Share
EVAX
$17.4M
| $2.97M | 1.38% | 1,214,126 | – | – |
|
7
Sutro Biopharma
STRO
$72.7M
| $1.94M | 0.9% | 2,723,509 | – | – |
|
8
LAVA Therapeutics
LVTX
$41.3M
| $1.52M | 0.7% | 1,149,345 | – | – |
|
9
Viridian Therapeutics
VRDN
$1.5B
| $1.31M | 0.61% | 93,414 | – | – |
|
10
Xilio Therapeutics
XLO
$36.3M
| $1.01M | 0.47% | 1,483,758 | – | – |
|
11
Carisma Therapeutics
CARM
$8.98M
| $577K | 0.27% | 1,473,240 | – | – |
|
|
NEUP
12
Neuphoria Therapeutics Inc. Common Stock
NEUP
$21.3M
| $71.2K | 0.03% | 10,027 | – | – |
|
|
HURA
13
TuHURA Biosciences, Inc. Common Stock
HURA
$135M
| $31.1K | 0.01% | +13,950 | New | +$31.1K |
|